Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae
Clin Mol Hepatol. 2017;23(1):51-56.   Published online 2017 Mar 16     DOI: https://doi.org/10.3350/cmh.2016.0053
Citations to this article as recorded by Crossref logo
Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia
F. Ji, B. Wei, Y. H. Yeo, E. Ogawa, B. Zou, C. D. Stave, Z. Li, S. Dang, N. Furusyo, R. C. Cheung, M. H. Nguyen
Alimentary Pharmacology & Therapeutics.2018; 47(5): 550.     CrossRef
Asunaprevir/daclatasvir
Reactions Weekly.2017; 1653(1): 56.     CrossRef
Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
Reza Taherkhani, Fatemeh Farshadpour
World Journal of Hepatology.2017; 9(33): 1239.     CrossRef